These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 9025776

  • 1. A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis.
    Trump DL, Smith DC, Stiff D, Adedoyin A, Day R, Bahnson RR, Hofacker J, Branch RA.
    Cancer Chemother Pharmacol; 1997; 39(4):349-56. PubMed ID: 9025776
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial.
    Sutton LM, Warmuth MA, Petros WP, Winer EP.
    Cancer Chemother Pharmacol; 1997; 40(4):335-41. PubMed ID: 9225952
    [Abstract] [Full Text] [Related]

  • 3. Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer.
    Adamson PC.
    Leukemia; 1994; 8 Suppl 3():S22-5. PubMed ID: 7808020
    [Abstract] [Full Text] [Related]

  • 4. Phase I trial of all-trans retinoic acid in patients with treated head and neck squamous carcinoma.
    Park SH, Gray WC, Hernandez I, Jacobs M, Ord RA, Sutharalingam M, Smith RG, Van Echo DA, Wu S, Conley BA.
    Clin Cancer Res; 2000 Mar; 6(3):847-54. PubMed ID: 10741706
    [Abstract] [Full Text] [Related]

  • 5. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
    Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK, Prostate Cancer Clinical Trials Consortium.
    Cancer; 2008 Feb 01; 112(3):521-6. PubMed ID: 18085595
    [Abstract] [Full Text] [Related]

  • 6. Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer.
    Adamson PC.
    Leukemia; 1994 Nov 01; 8(11):1813-6. PubMed ID: 7967727
    [Abstract] [Full Text] [Related]

  • 7. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
    Lin CC, Hsu CH, Chen J, Tsai TC, Cheng AL, Pu YS.
    Anticancer Res; 2001 Nov 01; 21(2B):1385-90. PubMed ID: 11396219
    [Abstract] [Full Text] [Related]

  • 8. Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
    Wilding G, Soulie P, Trump D, Das-Gupta A, Small E.
    Cancer; 2006 May 01; 106(9):1917-24. PubMed ID: 16568471
    [Abstract] [Full Text] [Related]

  • 9. Phase II study of all-trans retinoic acid administered intermittently for hormone refractory prostate cancer.
    Culine S, Kramar A, Droz JP, Théodore C.
    J Urol; 1999 Jan 01; 161(1):173-5. PubMed ID: 10037392
    [Abstract] [Full Text] [Related]

  • 10. Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer.
    Budd GT, Adamson PC, Gupta M, Homayoun P, Sandstrom SK, Murphy RF, McLain D, Tuason L, Peereboom D, Bukowski RM, Ganapathi R.
    Clin Cancer Res; 1998 Mar 01; 4(3):635-42. PubMed ID: 9533531
    [Abstract] [Full Text] [Related]

  • 11. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
    Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L.
    J Clin Oncol; 2005 Jan 20; 23(3):455-60. PubMed ID: 15659491
    [Abstract] [Full Text] [Related]

  • 12. Pyrazoloacridine for the treatment of hormone-refractory prostate cancer.
    Small EJ, Fippin LJ, Whisenant SP.
    Cancer Invest; 1998 Jan 20; 16(7):456-61. PubMed ID: 9774952
    [Abstract] [Full Text] [Related]

  • 13. 13-cis-retinoic acid or all-trans-retinoic acid plus interferon-alpha in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trial.
    Weiss GR, Liu PY, Alberts DS, Peng YM, Fisher E, Xu MJ, Scudder SA, Baker LH, Moore DF, Lippman SM.
    Gynecol Oncol; 1998 Dec 20; 71(3):386-90. PubMed ID: 9887236
    [Abstract] [Full Text] [Related]

  • 14. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
    Hirano D, Minei S, Kishimoto Y, Yamaguchi K, Hachiya T, Yoshida T, Yoshikawa T, Endoh M, Yamanaka Y, Yamamoto T, Satoh Y, Ishida H, Okada K, Takimoto Y.
    Urol Int; 2005 Dec 20; 75(1):43-9. PubMed ID: 16037707
    [Abstract] [Full Text] [Related]

  • 15. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z, Cholovitsh M, Elezovitsh I, Vidovitsh A, Radoshevitsh-Radojkovitsh N, Boshkovitsh D, Novak A, Basara N.
    Srp Arh Celok Lek; 1995 Dec 20; 123(11-12):279-85. PubMed ID: 16296239
    [Abstract] [Full Text] [Related]

  • 16. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM.
    J Clin Oncol; 2005 May 20; 23(15):3343-51. PubMed ID: 15738542
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
    Smith DC, Chay CH, Dunn RL, Fardig J, Esper P, Olson K, Pienta KJ.
    Cancer; 2003 Jul 15; 98(2):269-76. PubMed ID: 12872344
    [Abstract] [Full Text] [Related]

  • 18. Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.
    Kolodziej M, Neubauer MA, Rousey SR, Pluenneke RE, Perrine G, Mull S, Boehm KA, Ilegbodu D, Asmar L.
    Clin Genitourin Cancer; 2006 Sep 15; 5(2):155-61. PubMed ID: 17026805
    [Abstract] [Full Text] [Related]

  • 19. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
    Nelius T, Reiher F, Lindenmeir T, Klatte T, Rau O, Burandt J, Filleur S, Allhoff EP.
    Onkologie; 2005 Nov 15; 28(11):573-8. PubMed ID: 16249643
    [Abstract] [Full Text] [Related]

  • 20. All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes.
    Adedoyin A, Stiff DD, Smith DC, Romkes M, Bahnson RC, Day R, Hofacker J, Branch RA, Trump DL.
    Cancer Chemother Pharmacol; 1998 Nov 15; 41(2):133-9. PubMed ID: 9443626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.